Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Correction: Improving the inhibitory effect of CXCR4 peptide antagonist in tumor metastasis with an acetylated PAMAM dendrimer
Changliang Liuac,
Hongyang Duanab,
Zijian Zhaoa,
Wenzhe Liab,
Lilusi Maa,
Xiaocui Fang*a,
Chen Wang*ac and
Yanlian Yang*ac
aCAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Key Laboratory of Biological Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, P. R. China. E-mail: fangxc@nanoctr.cn; wangch@nanoctr.cn; yangyl@nanoctr.cn; Tel: +86-10-82545561 Tel: +86-10-82545559
bAcademy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, P. R. China
cUniversity of Chinese Academy of Sciences, Beijing 100049, P. R. China
First published on 29th May 2019
Abstract
Correction for ‘Improving the inhibitory effect of CXCR4 peptide antagonist in tumor metastasis with an acetylated PAMAM dendrimer’ by Changliang Liu et al., RSC Adv., 2018, 8, 39948–39956.
The authors regret that the term “CXCL12” was incorrectly displayed as “CXCR12” in Scheme 1 and Fig. 6(a)–(c) in the original article. The correct versions of Scheme 1 and Fig. 6(a)–(c) are presented below.
 | ||
| Scheme 1 Schematic illustration of the preparation of the PAC80–E5 complex and the process of anti-tumor metastasis of the E5 peptide in the presence of PAC80. | ||
 | ||
| Fig. 6 (a–c) The inhibitory effect of E5 and PAC80–E5 on: (a) MCF-7; (b) MDA-MB-231; and (c) 4T1 cells detected by transwell assay. The CXCL12 supplemented sample without E5 or PAC80–E5 was set as 100% as the control. Error bars represent the standard deviation (n = 3). | ||
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
| This journal is © The Royal Society of Chemistry 2019 |